Ubilon : Each tablet contains Tibolone INN 2.5 mg.
* Treatment of the climacteric symptoms [hot flushes, sweating, vaginal dryness & less elasticity, mood disorders, anxiety etc.] resulting from the natural or artificial menopause.
* Prevention of postmenopausal and post oophorectomy osteoporosis and improvement of bone-mineral density in patients with established post-menopausal osteoporosis.
* Vaginal atrophy.
* Prevention of frequent UTI and urinary incontinence in postmenopausal women.
Osteoporosis: To prevent osteoporosis in post-menopausal women or after oophorectomy an uninterrupted longer (5-10 years) therapy of 2.5 mg daily is needed.
In case of natural menopause: To avoid irregular & abnormal bleeding, ubilon should be started at least 12 months after last natural bleeding.
In case of artificial menopause : Treatment should be started immediately.
In case of switching over from other conventional HRT:
If someone switches from estrogen-only preparation, she should start after a withdrawal bleeding.
If someone switches from sequential HRT preparation she should wait for the completion of the progestogen phase.
If someone switches from continuous combined HRT, she can start any time.
In case of missed pill: If no more than 12 hours have passed, the pill should be taken immediately. Otherwise the next dose should be continued as before.
Epilepsy or migraine.
Impaired carbohydrate metabolism.
Pregnant and lactating women.
Known or suspected hormone-dependent tumours.
Cardiovascular or cerebrovascular disorders such as thrombophlebitis, thromboembolic diseases or who has the history of these diseases [though there is no data; only theoretical knowledge reveals it].
Severe liver diseases.
Drugs that induce hepatic microsomal enzymes or other enzyme inducing drugs may accelerate the metabolism of tibolone and thus lower its activity.